ANDREADOU, IOANNA
ANDREADOU, IOANNA
SCIENZE MEDICHE
Chronic administration of Empagliflozin induces cardioprotection in vivo in absence of diabetes mellitus
2019-01-01 Abu Qourah, F; Nikolaou, PE ; Femmino, S; Tsoumani, M; Varela, A; Davos, C; Dimitriou, C; Kanaki, Z; Dimitriadis, G; Brizzi, MF; Iliodromitis EK; Andreadou, I
Chronic Empaglifozin treatment reduces myocardial infarct size in non-diabetic mice through STAT-3 mediated protection on microvascular endothelial cells and reduction of oxidative stress.
2021-01-01 Nikolaou PE, Efentakis P, Qourah FA, Femminò S, Makridakis M, Kanaki Z, Varela A, Tsoumani M, Davos CH, Dimitriou CA, Tasouli A, Dimitriadis G, Kostomitsopoulos N, Zuurbier CJ, Vlahou A, Klinakis A, Brizzi MF, Iliodromitis EK, Andreadou I.
Circulating blood cells and extracellular vesicles in acute cardioprotection
2019-01-01 Davidson S.M.; Andreadou I.; Barile L.; Birnbaum Y.; Cabrera-Fuentes H.A.; Cohen M.V.; Downey J.M.; Girao H.; Pagliaro P.; Penna C.; Pernow J.; Preissner K.T.; Ferdinandy P.
Editorial: The Challenge of New Therapeutic Approaches for Unmet Therapeutic Needs
2020-01-01 Rosa A.C.; Mio M.; Andreadou I.; Sumbayev V.V.
Effect of hyperglycaemia and diabetes on acute myocardial ischaemia–reperfusion injury and cardioprotection by ischaemic conditioning protocols
2020-01-01 Penna C.; Andreadou I.; Aragno M.; Beauloye C.; Bertrand L.; Lazou A.; Falcao-Pires I.; Bell R.; Zuurbier C.J.; Pagliaro P.; Hausenloy D.J.
Empagliflozin limits myocardial infarction in vivo and cell death in vitro: Role of STAT3, mitochondria, and redox aspects
2017-01-01 Andreadou, Ioanna; Efentakis, Panagiotis; Balafas, Evangelos; Togliatto, Gabriele; Davos, Constantinos H.; Varela, Aimilia; Dimitriou, Constantinos A.; Nikolaou, Panagiota-Efstathia; Maratou, Eirini; Lambadiari, Vaia; Ikonomidis, Ignatios; Kostomitsopoulos, Nikolaos; Brizzi, Maria F.; Dimitriadis, George; Iliodromitis, Efstathios K.
IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
2021-01-01 Lecour, Sandrine; Andreadou, Ioanna; Bøtker, Hans Erik; Davidson, Sean M; Heusch, Gerd; Ruiz-Meana, Marisol; Schulz, Rainer; Zuurbier, Coert J; Ferdinandy, Péter; Hausenloy, Derek J
Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling
2021-01-01 Andreadou I.; Daiber A.; Baxter G.F.; Brizzi M.F.; Di Lisa F.; Kaludercic N.; Lazou A.; Varga Z.V.; Zuurbier C.J.; Schulz R.; Ferdinandy P.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Chronic administration of Empagliflozin induces cardioprotection in vivo in absence of diabetes mellitus | 2019 | Abu Qourah, F; Nikolaou, PE ; Femmino, S; Tsoumani, M; Varela, A; Davos, C; Dimitriou, C; Kanaki, Z; Dimitriadis, G; Brizzi, MF; Iliodromitis EK; Andreadou, I | |
| Chronic Empaglifozin treatment reduces myocardial infarct size in non-diabetic mice through STAT-3 mediated protection on microvascular endothelial cells and reduction of oxidative stress. | 2021 | Nikolaou PE, Efentakis P, Qourah FA, Femminò S, Makridakis M, Kanaki Z, Varela A, Tsoumani M, Davos CH, Dimitriou CA, Tasouli A, Dimitriadis G, Kostomitsopoulos N, Zuurbier CJ, Vlahou A, Klinakis A, Brizzi MF, Iliodromitis EK, Andreadou I. | |
| Circulating blood cells and extracellular vesicles in acute cardioprotection | 2019 | Davidson S.M.; Andreadou I.; Barile L.; Birnbaum Y.; Cabrera-Fuentes H.A.; Cohen M.V.; Downey J.M.; Girao H.; Pagliaro P.; Penna C.; Pernow J.; Preissner K.T.; Ferdinandy P. | |
| Editorial: The Challenge of New Therapeutic Approaches for Unmet Therapeutic Needs | 2020 | Rosa A.C.; Mio M.; Andreadou I.; Sumbayev V.V. | |
| Effect of hyperglycaemia and diabetes on acute myocardial ischaemia–reperfusion injury and cardioprotection by ischaemic conditioning protocols | 2020 | Penna C.; Andreadou I.; Aragno M.; Beauloye C.; Bertrand L.; Lazou A.; Falcao-Pires I.; Bell R.; Zuurbier C.J.; Pagliaro P.; Hausenloy D.J. | |
| Empagliflozin limits myocardial infarction in vivo and cell death in vitro: Role of STAT3, mitochondria, and redox aspects | 2017 | Andreadou, Ioanna; Efentakis, Panagiotis; Balafas, Evangelos; Togliatto, Gabriele; Davos, Constantinos H.; Varela, Aimilia; Dimitriou, Constantinos A.; Nikolaou, Panagiota-Efstathia; Maratou, Eirini; Lambadiari, Vaia; Ikonomidis, Ignatios; Kostomitsopoulos, Nikolaos; Brizzi, Maria F.; Dimitriadis, George; Iliodromitis, Efstathios K. | |
| IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action | 2021 | Lecour, Sandrine; Andreadou, Ioanna; Bøtker, Hans Erik; Davidson, Sean M; Heusch, Gerd; Ruiz-Meana, Marisol; Schulz, Rainer; Zuurbier, Coert J; Ferdinandy, Péter; Hausenloy, Derek J | |
| Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling | 2021 | Andreadou I.; Daiber A.; Baxter G.F.; Brizzi M.F.; Di Lisa F.; Kaludercic N.; Lazou A.; Varga Z.V.; Zuurbier C.J.; Schulz R.; Ferdinandy P. |